Ticker

Regencell Bioscience is an early-stage bioscience company that has been working since 2014 to develop a marketable drug. The company's focus area is traditional Chinese medicine.

Regencell Bioscience Holdings Limited has surged 23,745% in 2025, reaching a $12b market cap despite having zero revenue. RGC's explosive upside is driven by float mechanics, with the founder and his wife locking up most of the free float. Recent SEC filings and a 35-for-1 reverse stock split have increased accessibility and meme stock potential, fueling further price momentum.

Regencell Bioscience's investor website explains that it is an early-stage bioscience company working on TCM. It lists indications such as neurocognitive disorders and infectious diseases as areas of interest but doesn't clearly explain what TCM is.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (NASDAQ:RGC) and Camping World Holdings, Inc. (NYSE:CWH). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.…

Finding top growth stocks with the kind of capital appreciation upside long-term investors are seeking is the name of the game for a solid majority of investors in the market right now.